Fox Chase Cancer Center
Video Player is loading.
10 seconds
Playback speed
2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunitinib - Which Drug Showed Greater Response in the 1st Line Advanced Disease? Did MK-6482 Show Clinical Activity in Clear Cell Disease?
By
Fox Chase Cancer Center
FEATURING
Elizabeth R. Plimack
By
Fox Chase Cancer Center
FEATURING
Elizabeth R. Plimack
Comments 0
Login to view comments.
Click here to Login
